X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: Looking back at the success of Part D in its first 10 years

By Nicole Longo  |    December 26, 2016
As 2016 comes to a close this week, Medicare Part D wraps up its first decade – and it’s been quite a busy decade. Today, more than 40 million people, including seniors and people living with...   Read More

Ask About Adherence: One tool for synchronizing and simplifying your medication routine

By Carolyn Ha  |    December 22, 2016
  Read More

Medicare Monday: New research finds trends in Average Sales Price of Part B drugs remains stable

By Kelsey Lang  |    December 19, 2016
Earlier this year, we looked at Average Sales Price (ASP) and how it works in Medicare Part B. As you may remember, ASP (the method for reimbursing drugs covered by Part B) is a market-based price...   Read More

New report provides recommendations for securing and protecting IP

By Mark Grayson  |    December 13, 2016
This week, the White House Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC) issued a Joint Strategic Plan outlining actions government, industry, educational institutions and...   Read More

Medicare Monday: Negotiation in Medicare Part D works

By Allyson Funk  |    December 12, 2016
Earlier this year, we highlighted a new QuintilesIMS Institute research brief that, for the first time, looked at Part D costs after accounting for rebates.   Read More

Video: Translating science into new medicines

By Andrew Powaleny  |    December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer, healthier...   Read More

Medicare Monday: Don’t forget! Medicare open enrollment ends Wednesday

By Nicole Longo  |    December 5, 2016
This Wednesday, December 7, marks the end of Medicare open enrollment. That means there are only a couple days left to review and make changes to your 2017 coverage.   Read More

World AIDS Day 2016: A decade of scientific innovation

By Andrew Powaleny  |    December 1, 2016
On World AIDS Day, we are reminded of the significant advances that have been made – many of which occurred over the past decade – to help transform HIV/AIDS from a once acutely fatal epidemic to a...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."